Indian TB market a “primary focus” for Genedrive (LON:GDR), says CEO: ProactiveInvestors Stocktube

ProactiveInvestors Stocktube

Published on Oct 11, 2016

David Budd, chief executive of molecular diagnostics firm Genedrive PLC (LON:GDR), says India will continue to be a “primary focus” for the company as it looks to address the tuberculosis (TB) problem in the country.

“The problem with TB is massive in India and the opportunity to really deliver something meaningful in healthcare in India is huge,” Budd tells Proactive Investors.

Currently, the Genedrive device is only used to detect TB in people, but the development of a Genedrive test for hepatitis C remains on track.

Budd thinks this will be prove to be “very valuable” to the company in the coming years and says the firm is targeting CE marking for the product in the spring of next year.

Touching on the refocus and reshuffle within the company, he explains that the company has “made huge strides” as it looks to reposition itself as a molecular diagnostics company.

“Diagnostics is the future and where we want to put or emphasis and our investment.”

http://www.4-traders.com/GENEDRIVE-PLC-4006926/
https://www.genedrive.com/

Genedrive PLC's buy rating reiterated at Peel Hunt. GBX 200 PT. https://t.co/FWr5DjTBLz $GDR #GDR

— US Consumer News (@ConsumerFeed) October 11, 2016